Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

BRTX , TPIA , ITCI , TSHA , OVIT
Sort by: Date|Relevance

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...
Featured Submission | August 13, 2021 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. Duchenne muscular dystrophy (DMD) research firm Solid Biosciences ...
Streetwise Reports | August 20, 2019 |

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...
Streetwise Reports | December 19, 2019 |

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector...
Mario Hose | March 4, 2020 |

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough

After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, bu...
Streetwise Reports | September 9, 2019 |

Fibrocell Science Shares Rise 60% on Acquisition News

Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. Cell and gene therapy company Fibrocell Science Inc. (FCSC:NASDAQ) , which focuses on transfo...
Streetwise Reports | September 16, 2019 |

Surface Oncology Shares Trade Up 40% on Phase1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. Clinical-...
Streetwise Reports | May 21, 2020 |

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure

Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. Gene-modified cellular and immune therapies company Enochian Biosciences Inc. (EN...
Streetwise Reports | June 9, 2020 |

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control

The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. In a July 31 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) presented two posters o...
Streetwise Reports | August 6, 2019 |
1 2 3 4 5 6 7 8 9 10 ...